# Sinocelltech

Source: https://onco.cc/companies/sinocelltech/  
OnCo record `sinocelltech` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sinocelltech is a China-based biotechnology company running 8 late-stage cancer trials of SCTB41, SCTB35 and SCTC21C in multiple myeloma, non-small-cell lung cancer and diffuse large B-cell lymphoma.

## Summary

Sinocelltech, based in Beijing, China, is a biotechnology company. Sinocelltech is a biopharmaceutical company that researches, manufactures and commercialises monoclonal antibodies, recombinant proteins and vaccines. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials (6 in phase 3), testing SCTB41, SCTB35, SCTC21C, SCTB39-1 and SCTB14 in multiple myeloma, non-small-cell lung cancer, diffuse large B-cell lymphoma and follicular lymphoma. The largest, NCT06041061 (A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years), plans to enrol 18000 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Sinocelltech Ltd.
- Tags: ctgov-sponsor
- HQ: Beijing
- Type: biotech
- Website: https://www.sinocelltech.com

## Sources

- Official website: https://www.sinocelltech.com
- ClinicalTrials.gov: trials led by Sinocelltech: https://clinicaltrials.gov/search?lead=Sinocelltech%20Ltd.

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [SCTB14](https://onco.cc/drugs/sctb14/), [SCTB35](https://onco.cc/drugs/sctb35/), [SCTB41](https://onco.cc/drugs/sctb41/), [SCTC21C](https://onco.cc/drugs/sctc21c/)
- trials: [A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study](https://onco.cc/trials/nct07609251/), [A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years](https://onco.cc/trials/nct06041061/), [A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma](https://onco.cc/trials/nct07570823/), [A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma](https://onco.cc/trials/nct07562022/), [A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant](https://onco.cc/trials/nct07297329/), [A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07362459/), [Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.](https://onco.cc/trials/nct06600022/), [Phase I/II Study of SCTB39-1 in Advanced Solid Tumours](https://onco.cc/trials/nct07050641/), [SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07662395/)

---
JSON: https://onco.cc/api/v1/entities/sinocelltech.json